// App-Quantinova.ai

: Prospective Outcomes of Second Line Therapy in Acute Gvhd: Six Month Freedom from Treatment Failure and Day 28 Response in a Multicentre Study

Researchers

Presenter

  • Rohini Radia

Principal Investigators

  • Arun Alfred

  • Matthew P. Collin

  • Maria H Gilleece

  • James E Griffin

  • Ann E. Hunter

  • Hannah Hunter

  • Harpreet Kaur

  • Nandita Khera

  • Kavita Raj

  • Emma Das-Gupta

  • Fiona Louise Dignan

  • Madan Jagasia

Medical Centers

  • Department of Haematology, Nottingham City Hospital, Nottingham, United Kingdom

  • Rotherham NHS Trust, Rotherham, United Kingdom

  • Newcastle University, Newcastle upon Tyne, United Kingdom

  • Department of Histopathology, Leeds Teaching Hospitals NHS Foundation Trust, Leeds, United Kingdom

  • Adult Bone Marrow Transplant, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom

  • Leicester Royal Infirmary, Leicester, UK

  • Derriford Hospital, Plymouth, United Kingdom

  • Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom

  • Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ

  • Department of Haematology, Kings College Hospital and Guys and St Thomas' NHS Foundation Trust, London, United Kingdom

  • Nottingham Univ. Hospitals NHS Trust, City Campus, Nottingham, GBR

  • Department of Clinical Haematology, Central Manchester University Hospital NHS Trust, Manchester, United Kingdom

  • Division of Epidemiology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

  • Autoimmune (AI)

Disease

  • Gaucher disease 2

  • Graft-versus-host disease

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Observational

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved